Across TCGA pan-cancer cohorts, FAM138E Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM138E data layer compared with 13 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher FAM138E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM138E expression acts as an unfavorable survival marker.
COAD are the cancer types where FAM138E Mutation most reproducibly stratifies survival.